Indication
EGFR Positive Non-Small Cell Lung Cancer
6 clinical trials
9 products
Clinical trial
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Product
BDTX-1535Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
osimertinibProduct
BLU-945Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-09
Product
pemetrexedProduct
carboplatinProduct
BLU-701Clinical trial
Efficacy and Safety of Furmonertinib for Epidermal Growth Factor Receptor (EGFR) Sensitive Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastasis: a Prospective Observational StudyStatus: Recruiting, Estimated PCD: 2024-09-30
Product
FurmonertinibClinical trial
First Line Osimertinib in the Real World: an Inter-regional Prospective Study: FLOWERStatus: Completed, Estimated PCD: 2022-06-01
Product
OsimertinibClinical trial
A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation MutationStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Product
Dacomitinib